Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Agenus ( (AGEN) ).
On June 3, 2025, Agenus Inc. announced a strategic collaboration with Zydus Lifesciences Ltd. involving the sale of its manufacturing operations to Zydus for up to $125 million. This agreement includes an upfront payment of $75 million and contingent payments of up to $50 million, alongside a $16 million equity investment by Zydus in Agenus. The collaboration aims to accelerate the development and commercialization of Agenus’ cancer immunotherapy drugs, botensilimab and balstilimab (BOT/BAL), by leveraging Zydus’ manufacturing capabilities and market presence in India and Sri Lanka. This partnership is expected to enhance Agenus’ operational capacity and market reach, while also establishing Zydus’ BioCDMO business in the U.S.
The most recent analyst rating on (AGEN) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.
Spark’s Take on AGEN Stock
According to Spark, TipRanks’ AI Analyst, AGEN is a Neutral.
The overall stock score reflects significant financial instability and valuation challenges, partially offset by promising technical indicators and positive developments from the earnings call. The company’s strategic initiatives and leadership changes offer some optimism, but the financial health requires substantial improvement to mitigate risks.
To see Spark’s full report on AGEN stock, click here.
More about Agenus
Agenus Inc. is a leading immuno-oncology company focused on expanding patient access to cancer immunotherapy through a comprehensive pipeline of immunological agents. Established in 1994, the company specializes in antibody therapeutics, adoptive cell therapies, and adjuvants, with robust development capabilities across commercial and clinical manufacturing facilities. Agenus is headquartered in Lexington, MA.
Average Trading Volume: 862,413
Technical Sentiment Signal: Sell
Current Market Cap: $113.2M
See more data about AGEN stock on TipRanks’ Stock Analysis page.